Results Healthcare has advised Servier on the out-licensing of the global rights to the Sym022 programme, an anti-LAG3 monoclonal antibody
- Service: Licensing
- Sector: Healthcare
- Sub Sector: Pharma & Biotech
- Engagement Type: Sell Side
The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together with its subsidiaries, the “Group”) announces that on May 18, 2022, Chia Tai‑Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of the Company, has entered into a definitive agreement with Symphogen A/S (“Symphogen”), acquiring the Sym022 programme, an anti-LAG3 monoclonal antibody (the “Product”). Symphogen is a wholly-owned subsidiary of Servier, a global independent pharmaceutical company, and is Servier’s Antibody Center of Excellence.
The Product is a recombinant, fully human effector-function attenuated anti-LAG-3 monoclonal antibody which has shown significant tumour growth inhibition potential in the pre-clinical stage. The Product has completed two phase 1 clinical trials and the results show it is safe and well-tolerated both as a monotherapy and in combination with other checkpoint inhibitors.
The transaction is subject to closing conditions and is expected to complete in June 2022. The sale of the Product was managed by Results Healthcare.
We greatly appreciated the support from Results in our divestiture of the non-core product SYM022, which we successfully sold to CTTQ/Sino. We were able to benefit from the Results network, their diligence in moving the project forwards and their experience in getting these types of deal across the finish line.
Global Head of Transactions